TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr.
TOKYO--(BUSINESS WIRE)--RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Norio Hamamatsu, President and CEO) signed a master service ...
When Japanese pharmaceutical company Daiichi Sankyo Co. discovered a groundbreaking cancer treatment, it turned to bigger Western drugmaker AstraZeneca Plc. to help commercialize the therapy that has ...
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has become the first drug to outperform chemotherapy in immunotherapy-ineligible metastatic ...
TOKYO, MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has entered into a global development and commercialization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback